China SXT Pharmaceuticals Statistics
Total Valuation
SXTC has a market cap or net worth of $793,358. The enterprise value is -$7.52 million.
| Market Cap | 793,358 |
| Enterprise Value | -7.52M |
Important Dates
The last earnings date was Monday, August 19, 2019, before market open.
| Earnings Date | Aug 19, 2019 |
| Ex-Dividend Date | n/a |
Share Statistics
SXTC has 727,851 shares outstanding.
| Shares Outstanding | 727,851 |
| Owned by Insiders (%) | 25.06% |
| Owned by Institutions (%) | 0.51% |
| Float | 589,603 |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 26.52 |
| Forward PS | n/a |
| PB Ratio | 0.16 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.47, with a Debt / Equity ratio of 0.62.
| Current Ratio | 1.47 |
| Quick Ratio | 1.40 |
| Debt / Equity | 0.62 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -31.95 |
Financial Efficiency
Return on equity (ROE) is -141.60% and return on invested capital (ROIC) is -161.94%.
| Return on Equity (ROE) | -141.60% |
| Return on Assets (ROA) | -76.90% |
| Return on Capital (ROIC) | -161.94% |
| Revenue Per Employee | $384 |
| Profits Per Employee | -$181,235 |
| Employee Count | 78 |
| Asset Turnover | 0.00 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | 1.12 |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 1.10 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 48.48 |
| Average Volume (20 Days) | 768,453 |
Short Selling Information
| Short Interest | 37,112 |
| Short Previous Month | 49,458 |
| Short % of Shares Out | 4.79% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.07 |
Income Statement
In the last 12 months, SXTC had revenue of $29,919 and -$14.14 million in losses. Loss per share was -$26.97.
| Revenue | 29,919 |
| Gross Profit | 1.11M |
| Operating Income | -13.32M |
| Pretax Income | -14.14M |
| Net Income | -14.14M |
| EBITDA | -13.36M |
| EBIT | -13.71M |
| Loss Per Share | -$26.97 |
Balance Sheet
The company has $11.47 million in cash and $3.15 million in debt, giving a net cash position of $8.31 million or $11.42 per share.
| Cash & Cash Equivalents | 11.47M |
| Total Debt | 3.15M |
| Net Cash | 8.31M |
| Net Cash Per Share | $11.42 |
| Equity (Book Value) | 5.08M |
| Book Value Per Share | 6.97 |
| Working Capital | 4.30M |
Cash Flow
In the last 12 months, operating cash flow was -$111,200 and capital expenditures -$50,569, giving a free cash flow of -$161,769.
| Operating Cash Flow | -111,200 |
| Capital Expenditures | -50,569 |
| Free Cash Flow | -161,769 |
| FCF Per Share | -$0.32 |
Margins
Gross margin is 3,703.22%, with operating and profit margins of -44,530.39% and -47,248.64%.
| Gross Margin | 3,703.22% |
| Operating Margin | -44,530.39% |
| Pretax Margin | -47,248.64% |
| Profit Margin | -47,248.64% |
| EBITDA Margin | -44,641.31% |
| EBIT Margin | -45,814.74% |
| FCF Margin | -540.69% |
Dividends & Yields
SXTC does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1,512.49% |
| Shareholder Yield | -1,512.49% |
| Earnings Yield | -1,781.83% |
| FCF Yield | -20.39% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on October 5, 2023. It was a reverse split with a ratio of 1:25.
| Last Split Date | Oct 5, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
SXTC has an Altman Z-Score of -5.7 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -5.7 |
| Piotroski F-Score | 4 |